Regen Biopharma reduces convertible note principal by $967,830 via equity and cash

Regen BioPharma Inc

Satisfied $967,830 of principal and $539,392 in fees/interest through 706M common shares, 23.7M Series A preferred, and $218,529 cash.
Outstanding convertible note principal fell from $2.36M (June 30, 2021) to $1.40M (November 4, 2021).
Total debt reduction of approximately $1.51M includes principal, fees, penalties, and accrued interest.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.